358
Participants
Start Date
October 1, 2019
Primary Completion Date
December 31, 2024
Study Completion Date
December 31, 2024
Direct Oral Anticoagulants
Consecutive adult patients with objectively diagnosed unusual site venous thrombosis and treated with one of the DOAC (e.g. apixaban, dabigatran, edoxaban, rivaroxaban) will be eligible for this observational prospective registry
Henry Ford Health System, Detroit
Ottawa Hospital Research Institute, Ottawa
CHU Amiens Picardie, Amiens
Hôpital de la Cavale Blanche, Brest
Hôpital Edouard Herriot, Lyon
Hopital Louis Mourier, Paris
Hôpital Européen Georges Pompidou, Paris
Centre Hospitalier Universitaire de Saint-Etienne, Saint-Etienne
Sheba medical center, Tel Litwinsky
Azienda Ospedaliera Universitaria di Bologna, Bologna
Ospedale Maggiore, Bologna, Bologna
Ospedale Sant'Anna, ASST Lariana, Como
Ospedale Policlinico San Martino, Genova
Ospedale San Paolo, Milan
University Hospital of Padova, Padua
Catholic University, Rome
Sapienza Università di Roma, Rome
University of Insubria, Varese
University of Malta, Msida
Radboud University Medical Center Nijmegen, Nijmegen
University Medical Centre Ljubljana, Ljubljana
Clinica Universidad de Navarra, Madrid
Virgen del Rocío Hospital and Instituto de Biomedicina, Seville
King Chulalongkorn Memorial Hospital, Bangkok
Università degli Studi dell'Insubria
OTHER
University of Malta
OTHER